IMM-R

IMM-R is a Berlin-based biotechnology company focused on developing innovative immuno-oncology therapies that reprogram the tumor microenvironment. The company's core technology centers on the selective depletion of tumor-associated macrophages (TAMs), specifically the M2-like subpopulation that promotes tumor growth and suppresses immune responses. IMM-R's lead program, IMMR-01, is a targeted therapeutic that specifically binds to the CD163 receptor, a marker highly expressed on immunosuppressive macrophages. By eliminating these cells, IMM-R aims to restore the body's natural anti-tumor immunity and enhance the efficacy of existing treatments like checkpoint inhibitors. The company was founded by experts in lipid metabolism and immunology and is supported by venture capital from the High-Tech Gründerfonds.